Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NKG2D CAR mRNA-engineered NK cells
- Development stage
- Preclinical
- Lead developer
- PersonGen BioTherapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Intracerebroventricular, Intraperitoneal
01
Overview
NKG2D CAR mRNA-engineered NK cells are a form of cell therapy in which natural killer (NK) cells are genetically modified using messenger RNA (mRNA) to express a chimeric antigen receptor (CAR) that targets ligands for the activating receptor NKG2D. This engineering enhances the ability of NK cells to recognize and kill tumor cells expressing NKG2D ligands. The approach is being investigated as an immunotherapy for both hematological malignancies and solid tumors, with preclinical studies showing enhanced anti-tumor activity compared to conventional memory CAR-T cell therapies. Some constructs also coexpress cytokines such as IL-15 to further boost anti-tumor efficacy[1].
- Other names
- NKG2D-CAR-NK cellsNKG-2D-CAR-NK cellsNKG 2D-CAR-NK cellsNKG2D chimeric antigen receptor mRNA-engineered natural killer cellsNKG-2D chimeric antigen receptor mRNA-engineered natural killer cellsNKG 2D chimeric antigen receptor mRNA-engineered natural killer cells
02
Targets
MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on NKG2D CAR mRNA-engineered NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NKG2D CAR mRNA-engineered NK cells.